top of page

Work Packages

SUMMIT has established an integrated framework of expertise involving ni-neteen European academic institutions, one SME (small and medium sized enterprises) along with six Pharma partners. The team combines compe-tencies from a wide range of disciplines including molecular and cellular biology, genetics, animal models, bioinformatics and imaging technologies.

     Retinopathy                   Nephropathy           Cardiovascular Disease


To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

  • the identification of patients at high risk of diabetes complications

  • the monitoring of the complications' progression and patients‘ response to therapy 

To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.

Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

Related Sites

bottom of page